The number of installments for satisfying a milestone payment associated with a collaborative agreement.

No definition available.

Name:	aciu_CollaborativeAgreementMilestonePaymentNumberOfInstallments
Namespace Prefix:	aciu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment(s) received for milestone payments associated with a collaborative agreement.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementMilestonePaymentReceived
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Period of time that notice is required to be given for cancellation of the collaborative agreement contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementNoticeOfContractTerminationPeriod
Namespace Prefix:	aciu_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The total potential value of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	aciu_CollaborativeAgreementPotentialValue
Namespace Prefix:	aciu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The number of representatives in a joint steering committee by each party as per the agreement.

+ References

No definition available.

+ Details

Name:	aciu_NumberOfRepresentativesInJointSteeringCommitteeByEachParty
Namespace Prefix:	aciu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity’s future performance).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 105
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 116
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_ContractAssets
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.

+ References

+ Details

Name:	ifrs-full_ContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of current contract liabilities. [Refer: Contract liabilities]

+ References

+ Details

Name:	ifrs-full_CurrentContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of an entity’s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.

+ References

+ Details

Name:	ifrs-full_ReceivablesFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 120
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=aciu_TauMorphomerSmallMoleculeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_MilestonePaymentsCommercialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_ResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_RightOfUseLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillyFirstAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_TypesOfContractsAxis=aciu_CollaborationAgreementWithLillySecondAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_PerformanceObligationsAxis=aciu_PhaseTwoClinicalStudyLicensedProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contract revenues, Morphomer Tau small molecule - 2018 license agreement with Eli Lilly and Company (Details) SFr in Thousands	12 Months Ended
	Dec. 31, 2021 CHF (SFr) Representative Installment	Dec. 31, 2020 CHF (SFr)	Dec. 31, 2019 CHF (SFr)	Mar. 31, 2020 CHF (SFr)	Mar. 31, 2019 CHF (SFr)
Contract revenues [Abstract]
Recognized revenues	SFr 0	SFr 15,431	SFr 110,456
Deferred income	717	306	4,477
2018 License Agreement with Eli Lilly and Company [Member]
Contract revenues [Abstract]
Recognized revenues	0	14,348	105,662
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly and Company [Member]
Contract revenues [Abstract]
Milestone payment received	SFr 40,000
Up-front consideration received					SFr 80,000
Period to provide notice of termination of agreement	3 months
Number of representatives in joint steering committee by each party \| Representative	3
Recognized revenues	SFr 0	14,300	SFr 105,700
Deferred income	0
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly and Company [Member] \| Clinical and Regulatory [Member]
Contract revenues [Abstract]
Expected transaction price allocation	880,000
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly and Company [Member] \| Commercial [Member]
Contract revenues [Abstract]
Expected transaction price allocation	900,000
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly and Company [Member] \| Research and Development [Member]
Contract revenues [Abstract]
Deferred research and development costs	6,900
Recognized revenues	6,900
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly and Company [Member] \| Right-of-use License [Member]
Contract revenues [Abstract]
Expected transaction price allocation	SFr 73,100
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly, First Amendment [Member]
Contract revenues [Abstract]
Total potential collaboration agreement value					60,000
Number of installments \| Installment	2
Milestone payment receivable				SFr 30,000	SFr 30,000
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly, Second Amendment [Member]
Contract revenues [Abstract]
Number of installments \| Installment	2
Milestone payment receivable				SFr 10,000
Morphomer Tau Small Molecule [Member] \| 2018 License Agreement with Eli Lilly, Second Amendment [Member] \| Phase 2 Clinical Study Licensed Product [Member]
Contract revenues [Abstract]
Milestone payment receivable		SFr 60,000